ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Neoplasms
  • Quinazolines

abstract

  • ZD1839 was well tolerated, with DLT observed at a dose well above that at which antitumor activity was seen. Pharmacokinetic analysis confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation. Phase II monotherapy and phase III combination trials in NSCLC are being conducted to investigate further the efficacy, tolerability, and optimal daily dose of ZD1839.

publication date

  • May 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2002.10.112

PubMed ID

  • 11980995

Additional Document Info

start page

  • 2240

end page

  • 50

volume

  • 20

number

  • 9